Eagle Pharmaceuticals Inc-DE

EGRX70

High Value

$4.25arrow_drop_down3.18%-$0.14

High Value

Penny Stock

EGRX70

$4.25

arrow_drop_down3.18%-$0.14

High Value

Penny Stock

Performance History

Key Stats
Open	$4.41
Prev. Close	$4.39
EPS	0.85
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$56.82M

	LOW	HIGH
Day Range	4.13	4.41
52 Week Range	3.21	17.54

Ratios

Revenue	-





EPS	0.85

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Eagle Pharmaceuticals Inc-DE (EGRX)

Eagle Pharmaceuticals Inc-DE (EGRX) is a pharmaceutical company engaged in the development and commercialization of injectable products. The company's product portfolio includes both branded and generic drugs, with a focus on oncology, critical care, and orphan diseases. The company's mission is to improve patient outcomes by providing innovative and cost-effective treatment options.

Eagle Pharmaceuticals Inc-DE (EGRX) is a publicly traded company listed on the Nasdaq Stock Market. As of the latest available data, the stock price of EGRX was $75.50 per share. The stock has a 52-week range of $42.15 to $94.75. The day range for the stock is $74.90 to $75.70. The company has a market capitalization of $1.31 billion.

Websitecall_made

Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
CEO: Mr. Scott L. Tarriff
Headquarters: Woodcliff Lake
Employees: 134
Exchange: NASDAQ

add Eagle Pharmaceuticals Inc-DE to watchlist

Keep an eye on Eagle Pharmaceuticals Inc-DE

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the market capitalization of Eagle Pharmaceuticals Inc-DE (EGRX)?

Eagle Pharmaceuticals Inc-DE (EGRX) has a market capitalization of $56.82M. The average daily trading volume is 94.94K, indicating the stock's liquidity and investor engagement.

help

What is Eagle Pharmaceuticals Inc-DE's (EGRX) price per share?

The current price per share for Eagle Pharmaceuticals Inc-DE (EGRX) is $4.25. The stock has seen a price change of -$0.14 recently, indicating a -3.19% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Eagle Pharmaceuticals Inc-DE (EGRX)?

For Eagle Pharmaceuticals Inc-DE (EGRX), the 52-week high is $17.54, which is 312.71% from the current price. The 52-week low is $3.21, the current price is 32.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Eagle Pharmaceuticals Inc-DE (EGRX) a growth stock?

Eagle Pharmaceuticals Inc-DE (EGRX) has shown an average price growth of 0.41% over the past three years. It has received a score of 14 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eagle Pharmaceuticals Inc-DE as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Eagle Pharmaceuticals Inc-DE (EGRX) stock price performance year to date (YTD)?

As of the latest data, Eagle Pharmaceuticals Inc-DE (EGRX) has a year-to-date price change of -24.91%. Over the past month, the stock has experienced a price change of -6.18%. Over the last three months, the change has been 13.94%. Over the past six months, the figure is -33.07%. Looking at a longer horizon, the five-year price change stands at -92.27%.

help

Is Eagle Pharmaceuticals Inc-DE (EGRX) a profitable company?

Eagle Pharmaceuticals Inc-DE (EGRX) has a net income of -$2.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 70.01% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 15.94% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 84.56%, providing insight into the company's sales performance and growth. The gross profit is $221.67M. Operating income is noted at $53.45M. Furthermore, the EBITDA is $77.5M.

News

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

MAJOR SHAREHOLDER ANNOUNCEMENTS

5/22/2024

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

MAJOR SHAREHOLDER ANNOUNCEMENTS

4/12/2024

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

COMPANY ANNOUNCEMENT

PATENTS

1/18/2024

Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City